Researchers at the Children’s Cancer Institute Australia (CCIA) are using the ACRF Drug Discovery Centre for Childhood Cancer to enhance a recent breakthrough in lung cancer research.
Every year more than 9,000 Australians are diagnosed with non-small cell lung cancer. It is one of the most lethal forms of cancer. But while looking for ways to treat childhood solid cancer tumours, CCIA found a promising new therapy technique for lung cancer patients in Australia and throughout the world.
By using a gene-silencing approach on a structural protein in lung cancer cells, which is otherwise drug-resistant, CCIA’s therapy aims to increase the sensitivity of the tumour to standard chemotherapy drugs.
“This therapy… has direct clinical relevance for the more than 9,000 Australians diagnosed with non-small cell lung cancer every year,” said Professor Maria Kavallaris, head of the Pharmacoproteomics Program at CCIA.
CCIA scientists have been working closely an Australian biotechnology company with a dominant technology for silencing genes, to bring this new therapy from the lab to the clinic.
Click here to view the CCIA media release